Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression data from mouse lung

ABSTRACT: Female Crlj:CD1(ICR) mice were fed diets containing 0 (control),20, 500, 2500 and 5000 ppm permethrin for periods of 7 days. We used microarrays to evaluate gene expression profiling in mouse lung at the early phase of treatment with permethrin.

ORGANISM(S): Mus musculus

PROVIDER: GSE174300 | GEO | 2021/09/27

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from mouse lung from mice fed diets containing permethrin

Project description:Female Crlj:CD1(ICR) mice were fed diets containing 0 (control), 5000 and 10000 ppm permethrin and 2500 ppm isoniazid (positive control for tumor induction) for periods of 7 and 14 days. We used microarrays to evaluate gene expression profiling in mouse lung at the early phase of treatment with permethrin and isoniazid.

2018-12-21 | GSE92688 | GEO

Expression data from mouse liver at the early phase of treatment with permethrin or clofibrate

Project description:Crlj:CD1(ICR) female mice were fed diets containing 0 ppm (control), 5000 ppm permethrin, and 5000 ppm clofibrate for periods of 2 weeks. We used microarrays to evaluate gene expression profiling in mouse liver at the early phase of treatment with permethrin or clofibrate.

2019-12-10 | GSE124081 | GEO

Diosgenin supplementation effect on liver

Project description:Expression profile of liver of ICR mice (13-week old) treated with control diet (CRF-1) or CRF-1 containing 500 ppm diosgenin for 4 weeks. Nine-week old ICR mice were fed with a basal diet (CRF-1) or that containing 500 ppm diosgenin for 4 weeks ad libitum (n = 3 in each group). Food intake and body weight were measured on a weekly basis for the duration of the study.

2010-10-08 | E-GEOD-24580 | biostudies-arrayexpress

Human hepatocytes support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogen sodium phenobarbital in an in vivo study using a chimeric mouse with humanized liver

Project description:This SuperSeries is composed of the SubSeries listed below. Male CD-1 mice and WH rats (4 animals/dose) were fed diets containing 0 (control) or 2500 ppm NaPB for 7 days. Male chimeric mice (4-5 animals/dose) also fed diets containing 0 (control) or 1000 ppm NaPB for 7 days. Liver samples were used for gene expression analysis.

2014-08-29 | E-GEOD-57058 | biostudies-arrayexpress

Expression data from rat liver

Project description:BrlHan:WIST@Jcl(GALAS) male rats were fed diets containing 0 (control) and 3000 ppm epsilon-momfluorothrin for periods of 2 weeks. We used microarrays to evaluate gene expression profiling in rat liver at the early phase of treatment with epsilon-momfluorothrin.

2019-02-09 | GSE94738 | GEO

Diosgenin supplementation effect on liver

Project description:Expression profile of liver of ICR mice (13-week old) treated with control diet (CRF-1) or CRF-1 containing 500 ppm diosgenin for 4 weeks.

2010-10-08 | GSE24580 | GEO

Effect of treatment for three months with chemical carcinogen and non-carcinogens on liver miRNAome

Project description:Here, we examined the liver microRNA profile of male Fischer rats exposed through their diet to genotoxic (2-acetylaminofluorene) and epigenetic (phenobarbital, diethylhexylphthalate, methapyrilene HCL, monuron, and chlorendic acid) chemical hepatocarcinogens, as well as to non-hepatocarcinogenic treatments (benzophenone, and diethylthiourea) for three months. The aim of the study was to investigate how liver miRNA profiles relate to mode of action and carcinogenic potential of chemicals. In total miRNA profiles from 38 liver samples were examined. These included 3-5 samples for animal fed control diets or diet supplemented with designated chemicals. For each chemical a carcinogenic or a maximum tolerated dose was chosen based on published literature. The treatments were Diethylthiourea (DETU) 2500 ppm; Benzophenone (BP) 1250 ppm ; Monuron (MON) 1500 ppm ; Diethylhexylphthalate (DEHP) 12000 ppm ; Phenobarbital (PB) 1000 ppm; Chlorendic acid (CA) 1250 ppm; Methapyrilene HCl (MP) 250 ppm; 2-Acetyl aminofluorene (2-AAF) 40 ppm.

2013-07-03 | E-GEOD-48492 | biostudies-arrayexpress

A Clinical trial intended to compare two formulations of Capecitabine tablets, in patients with Breast Cancer, Dukes C Colon Cancer or Colorectal Cancer.

Project description:Intervention1: XELODAÂ -Capecitabine 500 mg tablets: Capecitabine 1250 mg/m2 administered twice daily orally :BD (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days including of three study periods. Control Intervention1: Capecitabine 500 mg tablets: Capecitabine 1250 mg/m2 administered twice daily orally; BD morning and evening; equivalent to 2500 mg/m2 total daily dose for 14 days including of three study periods. Primary outcome(s): To characterize the pharmacokinetic profile of the sponsors test formulation (Capecitabine Tablets 500 mg, Manufactured by Cadila Heathcare Limited, India) relative to that of reference formulation (XELODAÂ 500 mg tablets, Manufactured by Genentech USA Inc. USA) in patients of Metastatic Breast Cancer, Dukes C Colon Cancer or Metastatic Colorectal Cancer under fed condition and to assess the bioequivalence.Timepoint: Time points are 30 minutes prior to drug dosing and at 0.25hr, 0.50hr, 1hr, 1.5hr, 2hr, 2.5hr, 3hr, 4hr, 5hr, 6hr, 8hr and 10 hours post-dose. Study Design: Randomized, Crossover Trial Method of generating randomization sequence:Computer generated randomization Method of allocation concealment:An Open list of random numbers Blinding and masking:Open Label

| 2573937 | ecrin-mdr-crc

Dose and temporal effects of Phenobarbital on the liver miRNAome of male Fischer rats

Project description:Male Fischer rats were fed a control diet or a diet supplemented with 50, 500 or 1000 ppm Phenobarbital. The 500 and 1000 ppm PB doses induced a transient hyperplasia and a sustained hepatomegaly in treated animals. The animals were sacrificed and liver miRNAome was profiled in three animals per group after 1, 3, 7, and 14 days of treatment. The aim was to investigate the time and dose dependent effects of phenobarbital treatment on the liver miRNAome

2013-07-03 | GSE48489 | GEO

Triazole Antifungal Toxicogenomics: rat_repro_Testis

Project description:The modes of triazole reproductive toxicity have been characterized by an observed increased in serum testosterone and reduced insemination and fertility indices. The key events involved in the disruption in testosterone homeostasis and reduced fertility remain unclear. Gene expression analysis was conducted on liver and testis from Wistar Han IGS rats fed myclobutanil (M: 500, 2000 ppm), propiconazole (P: 500, 2500 ppm), or triadimefon (T: 500, 1800 ppm) from gestation day six to postnatal day 92. Pathway-based analysis highlighted key biological processes affected by all three triazoles in the liver including fatty acid catabolism, steroid metabolism, and xenobiotic metabolism. Triadimefon induced a distinctive expression profile of genes involved in liver sterol biosynthesis. There were no common pathways modulated by all three triazoles in the testis. Within the pathways identified in the liver, specific genes involved in phase I-III metabolism (Aldh1a1, Cyp1a1, Cyp2b2, Cyp3a1, Slco1a4, Udpgtr2), fatty acid metabolism (Cyp4a10, Pc, Ppap2b), and steroid metabolism (Srd5a1, Ugt1a1, Ugt2a1) were affected by all three triazoles. These modulated genes are part of a network of lipid and testosterone homeostasis pathways regulated by the constitutive androstane (CAR) and pregnane X (PXR) receptors. Gene expression profiles from this study indicate triazoles activate CAR and PXR; increase fatty acid catabolism, sterol biosynthesis, and steroid metabolism in the liver; constituting a plausible series of key events contributing to the observed disruption in testosterone homeostasis. Keywords: dose response, comparative toxicogenomics

2008-02-07 | GSE10412 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data